Dirk Kersten Sells 2,357 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 2,357 shares of the firm’s stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $35.06, for a total transaction of $82,636.42. Following the sale, the director now owns 190,939 shares in the company, valued at $6,694,321.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dirk Kersten also recently made the following trade(s):

• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.32, for a total value of $1,442,150.92.
• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95.

Dyne Therapeutics Stock Down 2.3 %

DYN opened at $33.83 on Friday. Dyne Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $47.45. The business has a 50 day moving average of $40.26 and a 200-day moving average of $33.89. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -8.52 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on DYN shares. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Piper Sandler reissued an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Morgan Stanley raised their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. raised their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. acquired a new position in Dyne Therapeutics in the 1st quarter valued at about $140,666,000. Vanguard Group Inc. boosted its holdings in shares of Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after acquiring an additional 1,110,629 shares during the period. Janus Henderson Group PLC grew its position in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after purchasing an additional 2,663,910 shares during the last quarter. Artal Group S.A. increased its stake in shares of Dyne Therapeutics by 24.6% during the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock worth $42,881,000 after purchasing an additional 114,888 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.